Published in Viruses on January 14, 2010
HIV-1 Protease: Structural Perspectives on Drug Resistance. Viruses (2009) 1.37
Research applications of proteolytic enzymes in molecular biology. Biomolecules (2013) 0.81
Construction of a molecular clone of ovine enzootic nasal tumor virus. Virol J (2016) 0.78
The N-end rule and retroviral infection: no effect on integrase. Virol J (2013) 0.77
Special issue: retroviral enzymes. Viruses (2010) 0.75
On the size of the active site in proteases. I. Papain. Biochem Biophys Res Commun (1967) 18.32
Murine leukemia virus protease is encoded by the gag-pol gene and is synthesized through suppression of an amber termination codon. Proc Natl Acad Sci U S A (1985) 5.36
The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol (1994) 3.95
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry (1995) 2.90
HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev (2008) 2.88
Amino- and carboxyl-terminal amino acid sequences of proteins coded by gag gene of murine leukemia virus. Proc Natl Acad Sci U S A (1978) 2.87
Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne). J Virol (1988) 2.76
Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature (1989) 2.72
Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Structure (2002) 2.69
Retroviral proteinases. Curr Top Microbiol Immunol (1990) 2.41
Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem Biol (2004) 2.39
The discovery of endogenous retroviruses. Retrovirology (2006) 2.18
Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. J Biol Chem (1991) 2.11
Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett (1991) 1.90
Active foamy virus proteinase is essential for virus infectivity but not for formation of a Pol polyprotein. J Virol (1995) 1.81
A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. J Biol Chem (1991) 1.59
HIV-1 protease: maturation, enzyme specificity, and drug resistance. Adv Pharmacol (2000) 1.48
Nucleotide sequence and protein analysis of a complex piscine retrovirus, walleye dermal sarcoma virus. J Virol (1995) 1.47
Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs. FEBS J (2005) 1.46
Comparison of the substrate-binding pockets of the Rous sarcoma virus and human immunodeficiency virus type 1 proteases. J Biol Chem (1993) 1.40
Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des (2008) 1.38
HIV-1 Protease: Structural Perspectives on Drug Resistance. Viruses (2009) 1.37
Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic*hydrophobic- or -aromatic*pro- cleavage sites. Biochemistry (1992) 1.33
HIV protease cleaves poly(A)-binding protein. Biochem J (2006) 1.30
Structure of an inhibitor complex of the proteinase from feline immunodeficiency virus. Nat Struct Biol (1995) 1.29
Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J Biol Chem (1990) 1.29
Simian foamy virus infection in humans: prevalence and management. Expert Rev Anti Infect Ther (2009) 1.23
Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. J Biol Chem (1992) 1.20
Mutations that alter the activity of the Rous sarcoma virus protease. J Biol Chem (1992) 1.20
Subsite preferences of retroviral proteinases. Methods Enzymol (1994) 1.19
Proteolytic processing of particle-associated retroviral polyproteins by homologous and heterologous viral proteinases. Eur J Biochem (1995) 1.18
Retroviral proteases. Genome Biol (2002) 1.17
Kinetic and modeling studies of S3-S3' subsites of HIV proteinases. Biochemistry (1992) 1.16
Proteolytic processing of foamy virus Gag and Pol proteins. Curr Top Microbiol Immunol (2003) 1.15
Studies on the role of the S4 substrate binding site of HIV proteinases. FEBS Lett (1991) 1.14
Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus Type-1 (HTLV-1). Int J Exp Pathol (2001) 1.06
HIV-1 protease inhibitors: effects on HIV-2 replication and resistance. Trends Pharmacol Sci (2007) 1.06
Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates. Methods Enzymol (1994) 1.03
Moloney murine leukemia virus protease: bacterial expression and characterization of the purified enzyme. Virology (1993) 1.02
Recombinant HIV2 protease processes HIV1 Pr53gag and analogous junction peptides in vitro. J Biol Chem (1990) 1.01
Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis. Virology (1996) 1.01
Role of the foamy virus Pol cleavage site in viral replication. J Virol (2007) 1.00
An engineered retroviral proteinase from myeloblastosis associated virus acquires pH dependence and substrate specificity of the HIV-1 proteinase. EMBO J (1992) 0.98
Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases. J Virol (2003) 0.97
Alteration of substrate and inhibitor specificity of feline immunodeficiency virus protease. J Virol (2000) 0.94
Cleavage of vimentin by different retroviral proteases. Arch Biochem Biophys (2000) 0.94
Specificity studies on retroviral proteinase from myeloblastosis-associated virus. Biochemistry (1991) 0.93
Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases. J Biol Chem (1994) 0.93
Effect of substrate residues on the P2' preference of retroviral proteinases. Eur J Biochem (1999) 0.93
Cloning, bacterial expression, and characterization of the Mason-Pfizer monkey virus proteinase. J Biol Chem (1995) 0.93
Specific in vitro cleavage of Mason-Pfizer monkey virus capsid protein: evidence for a potential role of retroviral protease in early stages of infection. Virology (2003) 0.92
Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell Leukemia virus type 1 protease. J Biol Chem (2004) 0.92
Molecular basis for the relative substrate specificity of human immunodeficiency virus type 1 and feline immunodeficiency virus proteases. J Virol (2001) 0.91
Amino acid preferences for a critical substrate binding subsite of retroviral proteases in type 1 cleavage sites. J Virol (2005) 0.91
Infection with HIV-2. AIDS (2001) 0.89
Comparative studies on the substrate specificity of avian myeloblastosis virus proteinase and lentiviral proteinases. J Biol Chem (1996) 0.89
Studies on the symmetry and sequence context dependence of the HIV-1 proteinase specificity. J Biol Chem (1997) 0.89
Purification and characterization of the mouse mammary tumor virus protease expressed in Escherichia coli. J Biol Chem (1992) 0.88
Studies on the substrate specificity of the proteinase of equine infectious anemia virus using oligopeptide substrates. Biochemistry (1993) 0.88
Characterization of the murine leukemia virus protease and its comparison with the human immunodeficiency virus type 1 protease. J Gen Virol (2006) 0.86
Kinetic and modeling studies of subsites S4-S3' of Moloney murine leukemia virus protease. J Biol Chem (1994) 0.86
Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site. J Virol (2008) 0.86
Characterization of the protease of a fish retrovirus, walleye dermal sarcoma virus. J Virol (2002) 0.86
Substrates and inhibitors of human T-cell leukemia virus type 1 (HTLV-1) proteinase. Leukemia (1997) 0.85
Expression, characterisation and mutagenesis of the aspartic proteinase from equine infectious anaemia virus. Eur J Biochem (1996) 0.85
Proteolytic events of HIV-1 replication as targets for therapeutic intervention. Curr Pharm Des (2003) 0.84
Molecular model of equine infectious anemia virus proteinase and kinetic measurements for peptide substrates with single amino acid substitutions. Biochemistry (1993) 0.82
Cloning of the bovine leukemia virus proteinase in Escherichia coli and comparison of its specificity to that of human T-cell leukemia virus proteinase. Biochim Biophys Acta (2000) 0.82
Human immunodeficiency virus type 1 capsid protein is a substrate of the retroviral proteinase while integrase is resistant toward proteolysis. Virology (2003) 0.81
Expression of the protease gene of equine infectious anemia virus in Escherichia coli: formation of the mature processed enzyme and specific cleavage of the gag precursor. Virology (1992) 0.79
Comparison of the specificity of homo- and heterodimeric linked HIV-1 and HIV-2 proteinase dimers. Protein Eng (1998) 0.79
Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases. J Gen Virol (2007) 0.79
Expression and characterization of human foamy virus proteinase. FEBS Lett (1999) 0.79
Synthetic HIV-2 protease cleaves the GAG precursor of HIV-1 with the same specificity as HIV-1 protease. Arch Biochem Biophys (1990) 0.79
Analysis of cross reactivity of retrovirus proteases using a vaccinia virus-T7 RNA polymerase-based expression system. J Gen Virol (1995) 0.79
Moloney murine leukemia virus protease expressed in bacteria is enzymatically active. Arch Virol (1998) 0.76
Chemical synthesis of a biotinylated derivative of the simian immunodeficiency virus protease. Purification by avidin affinity chromatography and autocatalytic activation. J Biol Chem (1992) 0.76
Molecular characterization of proteolytic processing of the Gag proteins of human spumaretrovirus. Methods Mol Biol (2005) 0.76